Circulating pro-surfactant protein b as a risk biomarker for lung cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 10, 2013, Pages 1756-1761

  Taguchi, Ayumu ^a   Hanash, Samir ^a   Rundle, Andrew ^b   McKeague, Ian W ^b   Tang, Deliang ^c   Darakjy, Salima ^b   Gaziano, J Michael ^d   Sesso, Howard D ^d   Perera, Frederica ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Epidemiology ^*  (United States)

^c Department of Medicine   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SURFACTANT PROTEIN B;

ADULT; AGED; ARTICLE; CANCER RISK; CAUCASIAN; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING;

BETA CAROTENE; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, FC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VITAMINS;

EID: 84886415690     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0251     Document Type: Article

References (23)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, FormanD. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. National Lung Screening Trial Research Team Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
4. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-29.
5. ShielsMS, Chaturvedi AK, Katki HA, Gochuico BR, Caporaso NE, Engels EA. Circulating markers of interstitial lung disease and subsequent risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2262-72.
6. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011;103:1112-22.
7. Taguchi A, Politi K, Pitteri SJ, LockwoodWW, Faca VM, Kelly-Spratt K, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011;20:289-99.
8. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
9. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
10. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008;300:2123-33.
11. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009;301:52-62.
12. Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg 1990;5:46-51.
13. Rundle AG, Vineis P, Ahsan H. Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 2005;14:1899-907.
14. Nguyen AB, Rohatgi A, Garcia CK, Ayers CR, Das SR, Lakoski SG, et al. Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2011;31:2136-43.
15. Robin M, Dong P, Hermans C, Bernard A, Bersten AD, Doyle IR. Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects. Eur Respir J 2002;20:1152-61.
16. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999;160:1843-50.
17. Epaud R, Ikegami M, Whitsett JA, Jobe AH, Weaver TE, Akinbi HT. Surfactant proteinBinhibits endotoxin-induced lung inflammation.Am J Respir Cell Mol Biol 2003;28:373-8.
18. Haczku A, Atochina EN, Tomer Y, Cao Y, Campbell C, Scanlon ST, et al. The late asthmatic response is linked with increased surface tension and reduced surfactant protein B in mice. Am J Physiol Lung Cell Mol Physiol 2002;283:L755-65.
19. McDowell SA, Gammon K, Bachurski CJ, Wiest JS, Leikauf JE, Prows DR, et al. Differential gene expression in the initiation and progression of nickel-induced acute lung injury. Am J Respir Cell Mol Biol 2000;23: 466-74.
20. Driscoll T, Nelson DI, Steenland K, Leigh J, Concha-Barrientos M, Fingerhut M, et al. The global burden of disease due to occupational carcinogens. Am J Ind Med 2005;48:419-31.
21. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-90.
22. Stahlman MT, Gray ME, Whitsett JA. Expression of thyroid transcription factor-1(TTF-1) in fetal and neonatal human lung. J Histochem Cytochem 1996;44:673-8.
23. Wender R, Fontham ET, Barrera E Jr., Colditz GA, Church TR, Ettinger DS, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 2013;63:107-17.